| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Polyps | 7 | 2022 | 23 | 1.770 |
Why?
|
| Adenoma | 6 | 2022 | 41 | 1.750 |
Why?
|
| Colorectal Neoplasms | 7 | 2022 | 82 | 1.630 |
Why?
|
| Colonoscopy | 15 | 2022 | 50 | 1.630 |
Why?
|
| Biopsy | 18 | 2021 | 239 | 1.430 |
Why?
|
| Liver | 14 | 2021 | 175 | 1.130 |
Why?
|
| Liver Neoplasms | 7 | 2018 | 106 | 1.130 |
Why?
|
| Esophagus | 4 | 2015 | 59 | 0.940 |
Why?
|
| Barrett Esophagus | 3 | 2014 | 11 | 0.940 |
Why?
|
| Colon | 8 | 2018 | 149 | 0.890 |
Why?
|
| Early Detection of Cancer | 5 | 2018 | 80 | 0.860 |
Why?
|
| Stomach Neoplasms | 4 | 2011 | 30 | 0.840 |
Why?
|
| Adenocarcinoma | 5 | 2015 | 194 | 0.820 |
Why?
|
| Neoplasms, Second Primary | 4 | 2022 | 32 | 0.820 |
Why?
|
| Middle Aged | 44 | 2021 | 9960 | 0.790 |
Why?
|
| Humans | 76 | 2022 | 29811 | 0.730 |
Why?
|
| Female | 54 | 2021 | 16410 | 0.720 |
Why?
|
| Esophagoscopy | 3 | 2015 | 13 | 0.720 |
Why?
|
| Male | 57 | 2020 | 15850 | 0.720 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2018 | 33 | 0.670 |
Why?
|
| Esophagitis | 3 | 2015 | 11 | 0.650 |
Why?
|
| Biomarkers, Tumor | 8 | 2018 | 198 | 0.630 |
Why?
|
| Population Surveillance | 4 | 2018 | 118 | 0.620 |
Why?
|
| Intestinal Mucosa | 11 | 2009 | 224 | 0.610 |
Why?
|
| Diagnostic Errors | 3 | 2014 | 40 | 0.610 |
Why?
|
| Gastrointestinal Hemorrhage | 5 | 2009 | 22 | 0.600 |
Why?
|
| Aged | 31 | 2018 | 9620 | 0.600 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2015 | 36 | 0.580 |
Why?
|
| Lymphoid Tissue | 2 | 2016 | 21 | 0.580 |
Why?
|
| Hirschsprung Disease | 1 | 2016 | 9 | 0.570 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 24 | 0.550 |
Why?
|
| Intestines | 3 | 2014 | 108 | 0.540 |
Why?
|
| Adenomyoma | 1 | 2015 | 1 | 0.540 |
Why?
|
| Gallbladder Neoplasms | 1 | 2015 | 5 | 0.540 |
Why?
|
| Enterocolitis | 2 | 2006 | 4 | 0.540 |
Why?
|
| Carcinoma | 1 | 2016 | 59 | 0.520 |
Why?
|
| Liver Cirrhosis | 4 | 2010 | 60 | 0.520 |
Why?
|
| Radiotherapy | 2 | 2015 | 53 | 0.510 |
Why?
|
| Radiation Injuries | 2 | 2015 | 34 | 0.510 |
Why?
|
| Quality of Health Care | 1 | 2016 | 138 | 0.500 |
Why?
|
| Adult | 35 | 2018 | 8741 | 0.490 |
Why?
|
| Colitis, Ulcerative | 4 | 2022 | 68 | 0.480 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2011 | 30 | 0.450 |
Why?
|
| Colonic Neoplasms | 6 | 2010 | 67 | 0.440 |
Why?
|
| Immunohistochemistry | 12 | 2015 | 411 | 0.440 |
Why?
|
| Ileum | 3 | 2011 | 24 | 0.440 |
Why?
|
| Liver Diseases | 2 | 2013 | 40 | 0.430 |
Why?
|
| Liver Transplantation | 3 | 2009 | 79 | 0.410 |
Why?
|
| Stomach | 3 | 2014 | 18 | 0.410 |
Why?
|
| Anus Neoplasms | 3 | 2020 | 6 | 0.400 |
Why?
|
| Giardiasis | 1 | 2011 | 1 | 0.400 |
Why?
|
| Giardia | 1 | 2011 | 2 | 0.400 |
Why?
|
| Leiomyoma | 1 | 2011 | 10 | 0.390 |
Why?
|
| Biopsy, Fine-Needle | 5 | 2018 | 51 | 0.370 |
Why?
|
| Retrospective Studies | 12 | 2020 | 3325 | 0.370 |
Why?
|
| Esophageal Neoplasms | 3 | 2014 | 46 | 0.370 |
Why?
|
| Mast Cells | 3 | 2007 | 25 | 0.360 |
Why?
|
| Duodenal Diseases | 2 | 2008 | 6 | 0.350 |
Why?
|
| Surgical Instruments | 1 | 2009 | 25 | 0.350 |
Why?
|
| Liver Failure | 1 | 2009 | 11 | 0.340 |
Why?
|
| Appendix | 1 | 2009 | 3 | 0.330 |
Why?
|
| Cystic Fibrosis | 1 | 2009 | 12 | 0.330 |
Why?
|
| Intussusception | 1 | 2009 | 6 | 0.330 |
Why?
|
| Appendicitis | 1 | 2009 | 17 | 0.330 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2022 | 24 | 0.320 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 8 | 0.320 |
Why?
|
| Plasmacytoma | 1 | 2008 | 18 | 0.320 |
Why?
|
| Hepatitis | 2 | 2006 | 9 | 0.320 |
Why?
|
| Iron Compounds | 1 | 2008 | 2 | 0.310 |
Why?
|
| Melanosis | 1 | 2008 | 3 | 0.310 |
Why?
|
| Diagnosis, Differential | 8 | 2015 | 399 | 0.310 |
Why?
|
| Iron | 1 | 2008 | 21 | 0.310 |
Why?
|
| Diarrhea | 3 | 2009 | 47 | 0.300 |
Why?
|
| Gastric Mucosa | 2 | 2006 | 13 | 0.280 |
Why?
|
| Aged, 80 and over | 12 | 2015 | 4930 | 0.280 |
Why?
|
| Mastocytosis, Systemic | 1 | 2006 | 6 | 0.270 |
Why?
|
| Mesenchymoma | 1 | 2006 | 2 | 0.270 |
Why?
|
| Arteriovenous Malformations | 1 | 2006 | 3 | 0.270 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2006 | 8 | 0.270 |
Why?
|
| Arteries | 1 | 2006 | 17 | 0.270 |
Why?
|
| Histocytochemistry | 3 | 2011 | 26 | 0.270 |
Why?
|
| Adrenal Glands | 1 | 2005 | 8 | 0.270 |
Why?
|
| Candidiasis | 1 | 2005 | 17 | 0.260 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 45 | 0.260 |
Why?
|
| Celiac Disease | 1 | 2005 | 9 | 0.260 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2018 | 31 | 0.250 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 6 | 0.250 |
Why?
|
| Fatty Liver, Alcoholic | 2 | 2019 | 11 | 0.250 |
Why?
|
| Granular Cell Tumor | 2 | 2007 | 5 | 0.250 |
Why?
|
| Lymph Nodes | 1 | 2005 | 71 | 0.250 |
Why?
|
| Cerebral Hemorrhage | 1 | 2005 | 131 | 0.230 |
Why?
|
| Autoantibodies | 1 | 2004 | 103 | 0.230 |
Why?
|
| Hepatomegaly | 2 | 2018 | 4 | 0.230 |
Why?
|
| Rectum | 4 | 2016 | 61 | 0.230 |
Why?
|
| Sarcoma | 1 | 2006 | 133 | 0.230 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2012 | 88 | 0.220 |
Why?
|
| Rectal Neoplasms | 2 | 2013 | 18 | 0.220 |
Why?
|
| Hepatectomy | 2 | 2018 | 54 | 0.220 |
Why?
|
| Glomus Tumor | 1 | 2002 | 1 | 0.220 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2002 | 1 | 0.220 |
Why?
|
| Liver Diseases, Alcoholic | 3 | 2009 | 45 | 0.210 |
Why?
|
| Mindfulness | 1 | 2022 | 34 | 0.210 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2017 | 10 | 0.200 |
Why?
|
| Fatal Outcome | 3 | 2006 | 60 | 0.200 |
Why?
|
| Oxidative Stress | 4 | 2009 | 131 | 0.190 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2021 | 13 | 0.190 |
Why?
|
| Prognosis | 4 | 2015 | 874 | 0.190 |
Why?
|
| Hyperplasia | 3 | 2018 | 15 | 0.190 |
Why?
|
| Condylomata Acuminata | 1 | 2020 | 1 | 0.180 |
Why?
|
| Microscopy | 2 | 2011 | 11 | 0.180 |
Why?
|
| Risk Factors | 5 | 2018 | 2465 | 0.180 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 37 | 0.180 |
Why?
|
| Adolescent | 7 | 2015 | 2332 | 0.180 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 25 | 0.180 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 636 | 0.170 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 1999 | 1 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 3 | 2006 | 151 | 0.170 |
Why?
|
| Iodide Peroxidase | 1 | 2019 | 34 | 0.170 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 532 | 0.160 |
Why?
|
| Infant, Newborn | 2 | 2020 | 618 | 0.160 |
Why?
|
| Portal Vein | 1 | 2018 | 39 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 3 | 2012 | 78 | 0.150 |
Why?
|
| Colon, Sigmoid | 2 | 2016 | 18 | 0.150 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 8 | 0.150 |
Why?
|
| Nitriles | 1 | 2017 | 13 | 0.150 |
Why?
|
| Triazoles | 1 | 2017 | 33 | 0.150 |
Why?
|
| Prospective Studies | 3 | 2013 | 1823 | 0.150 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 110 | 0.140 |
Why?
|
| Mass Screening | 2 | 2018 | 180 | 0.140 |
Why?
|
| Colon, Descending | 1 | 2016 | 1 | 0.140 |
Why?
|
| Ulcer | 2 | 2008 | 7 | 0.140 |
Why?
|
| Ethanol | 4 | 2019 | 134 | 0.140 |
Why?
|
| Gastroenterologists | 1 | 2016 | 1 | 0.140 |
Why?
|
| Infant | 2 | 2016 | 541 | 0.140 |
Why?
|
| Fatty Liver | 3 | 2019 | 31 | 0.140 |
Why?
|
| Metaplasia | 2 | 2014 | 11 | 0.140 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 263 | 0.140 |
Why?
|
| Cholecystectomy | 1 | 2015 | 16 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2013 | 778 | 0.130 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 142 | 0.130 |
Why?
|
| Eosinophilia | 2 | 2007 | 47 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2015 | 17 | 0.130 |
Why?
|
| HIV Infections | 2 | 2020 | 997 | 0.120 |
Why?
|
| Animals | 11 | 2019 | 4637 | 0.120 |
Why?
|
| Jejunal Diseases | 2 | 2005 | 5 | 0.120 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2014 | 1 | 0.120 |
Why?
|
| Adenoma, Liver Cell | 1 | 2014 | 1 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 32 | 0.120 |
Why?
|
| Alcoholism | 2 | 2019 | 83 | 0.120 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1993 | 7 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 1993 | 30 | 0.110 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 1 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 352 | 0.110 |
Why?
|
| Gastrointestinal Tract | 2 | 2011 | 56 | 0.110 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2013 | 4 | 0.110 |
Why?
|
| Needles | 1 | 2013 | 18 | 0.110 |
Why?
|
| Adenomatous Polyps | 1 | 2013 | 3 | 0.110 |
Why?
|
| Ultrasonography | 2 | 2018 | 224 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1993 | 91 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 22 | 0.110 |
Why?
|
| Chronic Disease | 4 | 2009 | 508 | 0.110 |
Why?
|
| Proctocolitis | 1 | 2012 | 2 | 0.110 |
Why?
|
| Lymphogranuloma Venereum | 1 | 2012 | 3 | 0.110 |
Why?
|
| Chlamydia trachomatis | 1 | 2012 | 17 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2012 | 4 | 0.100 |
Why?
|
| Anal Canal | 1 | 2012 | 3 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 63 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2018 | 3561 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1993 | 180 | 0.100 |
Why?
|
| Endotoxemia | 2 | 2009 | 29 | 0.100 |
Why?
|
| Nitric Oxide | 2 | 2009 | 103 | 0.100 |
Why?
|
| Mitotic Index | 1 | 2011 | 4 | 0.100 |
Why?
|
| Gastroscopy | 1 | 2011 | 8 | 0.100 |
Why?
|
| Oxidants | 1 | 2011 | 29 | 0.100 |
Why?
|
| Particulate Matter | 1 | 2011 | 22 | 0.100 |
Why?
|
| Cell Membrane Permeability | 1 | 2011 | 59 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 63 | 0.090 |
Why?
|
| Colectomy | 1 | 2010 | 20 | 0.090 |
Why?
|
| Membrane Glycoproteins | 4 | 1992 | 102 | 0.090 |
Why?
|
| alpha-Fetoproteins | 1 | 2010 | 5 | 0.090 |
Why?
|
| Pancreas | 3 | 2006 | 34 | 0.090 |
Why?
|
| alpha-Synuclein | 1 | 2012 | 139 | 0.090 |
Why?
|
| Incidental Findings | 1 | 2010 | 16 | 0.090 |
Why?
|
| Biomarkers | 3 | 2012 | 704 | 0.090 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 2010 | 1 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 2 | 2007 | 34 | 0.090 |
Why?
|
| Illinois | 2 | 2015 | 241 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2005 | 87 | 0.090 |
Why?
|
| Tomography | 1 | 2009 | 11 | 0.080 |
Why?
|
| Radiography, Abdominal | 1 | 2009 | 6 | 0.080 |
Why?
|
| Cell Count | 2 | 2007 | 97 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 92 | 0.080 |
Why?
|
| Dextran Sulfate | 1 | 2009 | 11 | 0.080 |
Why?
|
| Mucins | 1 | 2009 | 6 | 0.080 |
Why?
|
| Equipment Design | 1 | 2009 | 186 | 0.080 |
Why?
|
| Appendectomy | 1 | 2009 | 15 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 364 | 0.080 |
Why?
|
| Colitis | 1 | 2009 | 37 | 0.080 |
Why?
|
| Young Adult | 2 | 2013 | 1966 | 0.080 |
Why?
|
| Probiotics | 1 | 2009 | 20 | 0.080 |
Why?
|
| Cysts | 1 | 2008 | 16 | 0.080 |
Why?
|
| Bile Duct Neoplasms | 1 | 2008 | 11 | 0.080 |
Why?
|
| Cholangiocarcinoma | 1 | 2008 | 11 | 0.080 |
Why?
|
| Sleep Deprivation | 1 | 2009 | 64 | 0.080 |
Why?
|
| Duodenoscopy | 1 | 2008 | 2 | 0.080 |
Why?
|
| Anus Diseases | 1 | 2008 | 3 | 0.080 |
Why?
|
| Radiography | 1 | 2010 | 678 | 0.080 |
Why?
|
| Formaldehyde | 2 | 1998 | 14 | 0.080 |
Why?
|
| Chemokines, CC | 1 | 2007 | 8 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2009 | 463 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2007 | 23 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 379 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 15 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 102 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2007 | 47 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 43 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2001 | 107 | 0.070 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2007 | 53 | 0.070 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 744 | 0.070 |
Why?
|
| Homosexuality, Male | 2 | 2020 | 24 | 0.070 |
Why?
|
| Simplexvirus | 1 | 2006 | 9 | 0.070 |
Why?
|
| Rats | 5 | 2009 | 876 | 0.070 |
Why?
|
| Registries | 1 | 2008 | 191 | 0.070 |
Why?
|
| Endosonography | 1 | 2006 | 11 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 34 | 0.070 |
Why?
|
| Liposarcoma | 1 | 2006 | 17 | 0.070 |
Why?
|
| Obesity, Morbid | 1 | 2007 | 74 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 140 | 0.070 |
Why?
|
| Liver Glycogen | 1 | 2006 | 1 | 0.070 |
Why?
|
| Pancreatectomy | 2 | 2006 | 12 | 0.070 |
Why?
|
| Ranitidine | 1 | 2006 | 3 | 0.070 |
Why?
|
| Cetirizine | 1 | 2006 | 3 | 0.070 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2006 | 3 | 0.070 |
Why?
|
| Duodenum | 1 | 2006 | 11 | 0.070 |
Why?
|
| Tryptases | 1 | 2006 | 7 | 0.070 |
Why?
|
| Serine Endopeptidases | 1 | 2006 | 16 | 0.070 |
Why?
|
| Jugular Veins | 1 | 2005 | 3 | 0.070 |
Why?
|
| Carcinosarcoma | 1 | 2005 | 4 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 158 | 0.070 |
Why?
|
| Choristoma | 2 | 2003 | 8 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2005 | 20 | 0.070 |
Why?
|
| Duodenitis | 1 | 2005 | 1 | 0.060 |
Why?
|
| Ileitis | 1 | 2005 | 1 | 0.060 |
Why?
|
| Enteritis | 1 | 2005 | 2 | 0.060 |
Why?
|
| Intestinal Neoplasms | 1 | 2005 | 5 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 1 | 2005 | 5 | 0.060 |
Why?
|
| Hypertension | 1 | 2008 | 272 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 245 | 0.060 |
Why?
|
| Pyloric Antrum | 1 | 2005 | 2 | 0.060 |
Why?
|
| Gastritis | 1 | 2005 | 3 | 0.060 |
Why?
|
| Helicobacter pylori | 1 | 2005 | 4 | 0.060 |
Why?
|
| Helicobacter Infections | 1 | 2005 | 3 | 0.060 |
Why?
|
| Mice | 3 | 2019 | 1628 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 126 | 0.060 |
Why?
|
| Organ Size | 2 | 2018 | 107 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2003 | 101 | 0.060 |
Why?
|
| Endoscopy, Digestive System | 1 | 2003 | 9 | 0.060 |
Why?
|
| Child | 3 | 2007 | 1377 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 201 | 0.060 |
Why?
|
| Intestinal Obstruction | 1 | 2003 | 12 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1126 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2012 | 1184 | 0.050 |
Why?
|
| Prevalence | 1 | 2004 | 494 | 0.050 |
Why?
|
| Capillaries | 1 | 2002 | 13 | 0.050 |
Why?
|
| Disease Progression | 2 | 2022 | 812 | 0.050 |
Why?
|
| Permeability | 3 | 2009 | 139 | 0.050 |
Why?
|
| Vasculitis | 1 | 2002 | 32 | 0.050 |
Why?
|
| Ganglioneuroma | 1 | 2002 | 6 | 0.050 |
Why?
|
| Neuroblastoma | 1 | 2002 | 22 | 0.050 |
Why?
|
| Avena | 1 | 2001 | 5 | 0.050 |
Why?
|
| Digestive System | 1 | 2001 | 16 | 0.050 |
Why?
|
| Diet | 2 | 2019 | 172 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 147 | 0.050 |
Why?
|
| Drug Resistance | 3 | 2007 | 58 | 0.050 |
Why?
|
| Metalloproteins | 1 | 2001 | 1 | 0.050 |
Why?
|
| Hepatitis, Chronic | 1 | 2001 | 2 | 0.050 |
Why?
|
| Ribosomal Proteins | 1 | 2001 | 4 | 0.050 |
Why?
|
| Anastomosis, Surgical | 2 | 2003 | 34 | 0.050 |
Why?
|
| Observer Variation | 1 | 2021 | 119 | 0.050 |
Why?
|
| ABO Blood-Group System | 2 | 1990 | 7 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2001 | 69 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 86 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2022 | 249 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2001 | 66 | 0.040 |
Why?
|
| S100 Proteins | 1 | 1999 | 5 | 0.040 |
Why?
|
| Lysosomes | 1 | 1999 | 24 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 14 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 31 | 0.040 |
Why?
|
| Binge Drinking | 1 | 2019 | 10 | 0.040 |
Why?
|
| Triglycerides | 1 | 2019 | 45 | 0.040 |
Why?
|
| Hepatic Veins | 1 | 2018 | 7 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2009 | 65 | 0.040 |
Why?
|
| Ligation | 1 | 2018 | 31 | 0.040 |
Why?
|
| Swine | 1 | 2018 | 83 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 12 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 143 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2014 | 149 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 802 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2019 | 309 | 0.040 |
Why?
|
| Hamartoma | 1 | 1998 | 1 | 0.040 |
Why?
|
| Mitochondria | 2 | 2011 | 84 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 677 | 0.040 |
Why?
|
| Acute Disease | 2 | 2009 | 225 | 0.040 |
Why?
|
| Appendiceal Neoplasms | 1 | 1997 | 3 | 0.040 |
Why?
|
| Neurofibromatosis 1 | 1 | 1997 | 4 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 282 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 1996 | 57 | 0.030 |
Why?
|
| United States | 2 | 2018 | 2344 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2007 | 88 | 0.030 |
Why?
|
| Intestinal Absorption | 2 | 2009 | 42 | 0.030 |
Why?
|
| Body Weight | 2 | 2009 | 132 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 759 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2015 | 40 | 0.030 |
Why?
|
| Wound Healing | 1 | 1996 | 168 | 0.030 |
Why?
|
| Immunosuppressive Agents | 2 | 2007 | 135 | 0.030 |
Why?
|
| Glutamate-Ammonia Ligase | 1 | 2014 | 1 | 0.030 |
Why?
|
| Glypicans | 1 | 2014 | 1 | 0.030 |
Why?
|
| Serum Amyloid A Protein | 1 | 2014 | 2 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 3 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 8 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2014 | 8 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 21 | 0.030 |
Why?
|
| Liver Function Tests | 2 | 2006 | 27 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 53 | 0.030 |
Why?
|
| Ureter | 2 | 1990 | 15 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 1993 | 29 | 0.030 |
Why?
|
| Genetic Markers | 1 | 1993 | 45 | 0.030 |
Why?
|
| beta Catenin | 1 | 2014 | 49 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 1859 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 9 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 1992 | 270 | 0.030 |
Why?
|
| Unsafe Sex | 1 | 2012 | 7 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 2012 | 20 | 0.030 |
Why?
|
| Neurites | 1 | 2012 | 12 | 0.030 |
Why?
|
| Substance P | 1 | 2012 | 18 | 0.030 |
Why?
|
| Prednisone | 2 | 2003 | 68 | 0.030 |
Why?
|
| Coinfection | 1 | 2012 | 29 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 346 | 0.020 |
Why?
|
| Mutation | 1 | 1993 | 397 | 0.020 |
Why?
|
| District of Columbia | 1 | 2011 | 4 | 0.020 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2011 | 15 | 0.020 |
Why?
|
| Occludin | 1 | 2011 | 13 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2011 | 25 | 0.020 |
Why?
|
| Tight Junctions | 1 | 2011 | 28 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2011 | 28 | 0.020 |
Why?
|
| Air Pollution | 1 | 2011 | 17 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2011 | 55 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 62 | 0.020 |
Why?
|
| Particle Size | 1 | 2011 | 69 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 1247 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2011 | 109 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2011 | 110 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1990 | 9 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 130 | 0.020 |
Why?
|
| Inflammation | 2 | 2008 | 347 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 334 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 137 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2010 | 8 | 0.020 |
Why?
|
| Abdomen | 1 | 2010 | 11 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2011 | 177 | 0.020 |
Why?
|
| Abdominal Muscles | 1 | 2010 | 8 | 0.020 |
Why?
|
| Rectal Diseases | 1 | 2009 | 2 | 0.020 |
Why?
|
| Peroxidase | 1 | 2009 | 18 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 410 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 146 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 401 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 147 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2008 | 74 | 0.020 |
Why?
|
| Administration, Rectal | 2 | 1998 | 6 | 0.020 |
Why?
|
| Sexuality | 1 | 2008 | 18 | 0.020 |
Why?
|
| Receptors, CCR3 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Chemokine CCL26 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Interleukin-5 | 1 | 2007 | 10 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 35 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 435 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 329 | 0.020 |
Why?
|
| Dogs | 2 | 1998 | 261 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 155 | 0.020 |
Why?
|
| Splenectomy | 1 | 2006 | 7 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 102 | 0.020 |
Why?
|
| Gene Expression | 1 | 2007 | 231 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2007 | 92 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2007 | 324 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2006 | 25 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 279 | 0.020 |
Why?
|
| Glycogen Storage Disease | 1 | 2006 | 2 | 0.020 |
Why?
|
| Apoptosis | 1 | 2007 | 259 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1462 | 0.020 |
Why?
|
| Reoperation | 1 | 2010 | 927 | 0.020 |
Why?
|
| Cell Degranulation | 1 | 2005 | 7 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2005 | 18 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2005 | 9 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2007 | 654 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2005 | 43 | 0.020 |
Why?
|
| Japan | 1 | 2005 | 11 | 0.020 |
Why?
|
| Korea | 1 | 2005 | 10 | 0.020 |
Why?
|
| Proteins | 1 | 2005 | 71 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 86 | 0.020 |
Why?
|
| Heart Rate | 1 | 2005 | 152 | 0.020 |
Why?
|
| Atrophy | 1 | 2005 | 106 | 0.020 |
Why?
|
| Time Factors | 2 | 2001 | 1641 | 0.010 |
Why?
|
| Neutrophils | 1 | 2005 | 118 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2005 | 252 | 0.010 |
Why?
|
| Histamine H1 Antagonists | 1 | 2003 | 5 | 0.010 |
Why?
|
| Budesonide | 1 | 2003 | 5 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 2003 | 7 | 0.010 |
Why?
|
| Histamine H2 Antagonists | 1 | 2003 | 7 | 0.010 |
Why?
|
| Azathioprine | 1 | 2003 | 9 | 0.010 |
Why?
|
| Esophageal Perforation | 1 | 2003 | 7 | 0.010 |
Why?
|
| Proton Pump Inhibitors | 1 | 2003 | 13 | 0.010 |
Why?
|
| Gastrointestinal Motility | 1 | 2003 | 14 | 0.010 |
Why?
|
| Proton Pumps | 1 | 2003 | 14 | 0.010 |
Why?
|
| Catheterization | 1 | 2003 | 51 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2003 | 45 | 0.010 |
Why?
|
| Eosinophils | 1 | 2003 | 47 | 0.010 |
Why?
|
| Laparotomy | 1 | 2003 | 22 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 354 | 0.010 |
Why?
|
| Endotoxins | 1 | 2001 | 28 | 0.010 |
Why?
|
| Nausea | 1 | 2001 | 28 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2001 | 24 | 0.010 |
Why?
|
| Species Specificity | 1 | 2001 | 73 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2001 | 10 | 0.010 |
Why?
|
| Antibodies | 1 | 2001 | 66 | 0.010 |
Why?
|
| Liver Regeneration | 1 | 2001 | 23 | 0.010 |
Why?
|
| Epithelium | 2 | 1990 | 26 | 0.010 |
Why?
|
| Fatigue | 1 | 2001 | 63 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2001 | 108 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2001 | 159 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 258 | 0.010 |
Why?
|
| Hepacivirus | 1 | 2001 | 75 | 0.010 |
Why?
|
| Proctitis | 1 | 1998 | 3 | 0.010 |
Why?
|
| Compliance | 1 | 1998 | 6 | 0.010 |
Why?
|
| Manometry | 1 | 1998 | 20 | 0.010 |
Why?
|
| Collagen | 1 | 1998 | 102 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1996 | 12 | 0.010 |
Why?
|
| Microcirculation | 1 | 1996 | 39 | 0.010 |
Why?
|
| Hydroxyproline | 1 | 1996 | 6 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1997 | 403 | 0.010 |
Why?
|
| Tensile Strength | 1 | 1996 | 28 | 0.010 |
Why?
|
| Laparoscopy | 1 | 1997 | 143 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1996 | 44 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1996 | 221 | 0.010 |
Why?
|
| Survival Rate | 1 | 1996 | 376 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1991 | 325 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1990 | 149 | 0.010 |
Why?
|